Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: SpringWorks Therapeutics, Inc.

Market Cap 3.54B 3.07B 2.83B 2.65B 4.96B 339B 5.06B 33.79B 13.08B 163B 13.29B 13.01B 568B P/E Ratio 2023
-7.09x
P/E Ratio 2024 -10.4x
Enterprise Value 3.09B 2.68B 2.47B 2.31B 4.32B 296B 4.41B 29.45B 11.4B 142B 11.59B 11.34B 495B EV / Sales 2023
362,507,725x
EV / Sales 2024 11,654,155x
Free-Float
97.93%
Yield 2023 *
-
Yield 2024 -
1 year 46.72
Extreme 46.72
47.02
3 years 18
Extreme 18
62
5 years 13.6
Extreme 13.6
89.75
10 years 13.6
Extreme 13.6
96.48
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2022-12-31
Compliance Officer - 2021-12-31
Investor Relations Contact - 2018-07-31
Date Insider Type Main position Quantity % Market Cap.
25-06-30Issuer sale

General Counsel

397,427 0.5304%
25-06-30Issuer sale

Chief Technology Officer

369,000 0.4924%
25-06-30Issuer sale

Chief Technology Officer

151,946 0.2028%
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%-.--%+0.53%+72.44% 3.54B
+2.48%-2.41%+18.31%-18.63% 61.21B
+2.50%+4.43%+64.44%+218.90% 58.15B
-0.92%+28.60%+28.60%+28.60% 39.54B
+4.16%+16.25%-56.08%-64.88% 35.08B
+2.97%+1.01%+49.13%-36.69% 28.68B
+3.77%+7.15%+57.56%+74.69% 21.06B
+5.37%-7.44%+72.07%-61.34% 18.25B
-1.88%-5.07%-10.05%+93.76% 16.49B
+0.78%-1.57%+44.59%+101.10% 15.87B
Average +1.92%+1.13%+26.91%+40.80% 29.79B
Weighted average by Cap. +2.19%+1.42%+28.58%+44.49%

Financials

2023 2024
Net sales 5.45 4.73 4.36 4.08 7.63 521.56 7.79 51.98 20.12 251.41 20.45 20.01 874.15 191.59 166.26 153.26 143.6 268.31 18.34K 273.9 1.83K 707.81 8.84K 719.23 703.73 30.75K
Net income -325M -282M -260M -244M -455M -31.13B -465M -3.1B -1.2B -15.01B -1.22B -1.19B -52.17B -258M -224M -206M -193M -361M -24.72B -369M -2.46B -954M -11.91B -969M -948M -41.43B
Net Debt -656M -569M -524M -491M -918M -62.77B -937M -6.26B -2.42B -30.26B -2.46B -2.41B -105B -454M -394M -363M -340M -636M -43.47B -649M -4.33B -1.68B -20.95B -1.7B -1.67B -72.86B
Logo SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Employees
368
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SWTX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!